Descripción de la empresa
Cibus, Inc. operates within the healthcare sector, specifically functioning as a biotechnology firm dedicated to the development and licensing of gene-edited plant traits designed to enhance agricultural productivity. The company's core mission is to provide farmers with technologies that facilitate higher crop yields while simultaneously reducing reliance on chemical inputs such as fungicides, insecticides, and fertilizers, thereby promoting sustainable agricultural practices. Currently, the enterprise maintains a market capitalization of $128.50M and employs a workforce of 118 individuals to execute its strategic initiatives in agricultural innovation. When analyzing the financial scale, the market cap of $128.50M combined with a trailing twelve-month revenue of $3.64M indicates that the company is a small-cap entity with limited revenue generation relative to its equity value, suggesting a high-risk profile typical of early-stage biotechnology ventures where significant capital is often required before profitability is achieved.
Salud financiera
The financial performance for the trailing twelve months reveals a revenue stream of $3.64M contrasted sharply against a net income loss of $-127,085,000 and an EBITDA of $-61,541,000. The substantial disparity between the modest revenue figure and the massive net loss of approximately $127.1 million highlights a highly inefficient cost structure where operating expenses significantly outweigh revenue generation, a common characteristic in research-intensive biotechnology companies before product commercialization matures. Additionally, the company reports a free cash flow of $-51,790,624, which signifies a negative liquidity position where cash outflows for operations exceed cash inflows, thereby constraining the company's financial flexibility and necessitating external financing to sustain operations. The margin profile presents a complex picture with a gross margin of 100.0%, which typically suggests no cost of goods sold, yet is accompanied by an operating margin of -1273.3% and a profit margin of 0.0%, indicating that general and administrative costs are disproportionately high relative to sales. In terms of leverage, the balance sheet shows a total cash reserve of $9.92M against a total debt load of $267.96M, resulting in a debt-to-equity ratio of 1227.56, which clearly demonstrates a highly leveraged position where debt obligations far exceed available equity and cash reserves. Liquidity metrics further underscore financial stress, as evidenced by a current ratio of 0.72, meaning current assets are insufficient to cover current liabilities without raising additional capital. Finally, return metrics reflect the negative performance, with a return on equity of -221.0% and a return on assets of -12.9%, revealing that management effectiveness has been compromised by the inability to generate positive returns on the capital invested in the company's assets and shareholder equity.
Evaluación de valoración
Valuation multiples for Cibus, Inc. present anomalies due to the lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -7.95. The divergence between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in future earnings expectations that are currently negative, suggesting a trajectory where losses are expected to persist or deepen in the near term rather than immediate profitability. The price-to-book ratio stands at 3.96, indicating that the stock trades at a significant premium relative to its net book value, a valuation often seen in biotech firms where intangible assets and future pipeline potential are valued higher than current tangible assets. Alternative valuation metrics such as a price-to-sales ratio of 35.31 and an EV/EBITDA of -5.98 further illustrate that the market is valuing the company primarily on its revenue potential and strategic positioning rather than current earnings power. Price action analysis shows a 52-week high of $4.19 and a 52-week low of $1.09; without a specific current price in the provided facts, the valuation context suggests the stock trades within a highly volatile range defined by these extremes. The beta value of 1.93 indicates that the stock's price volatility is nearly double that of the broader market, meaning the asset is subject to significantly higher fluctuations in response to market movements compared to a standard equity investment.
Growth & Income
Growth metrics for the company indicate a revenue growth year-over-year of -12.8%, while earnings growth is listed as N/A due to the absence of profitable earnings in the prior period. The negative revenue growth rate suggests a contraction in sales, and since there are no positive earnings to compare against, the implication is that the company is currently unable to scale revenue effectively to offset its structural costs. As a non-dividend payer, the company does not offer a dividend yield or a payout ratio, which means it retains all earnings—or in this case, absorbs losses—to fund its operations and research rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by declining revenue and a complete absence of dividend income, reflecting a strategy focused on survival and future product development rather than current shareholder returns or financial stability.